Centessa Announces Q3 EPS of 41 Cents, Exceeding Consensus Estimate of 39 Cents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy CNTA?
Progress on OX2R Agonist Program: Centessa's ORX750 shows promising results as a potential best-in-class OX2R agonist for treating NT1, NT2, and IH, achieving significant outcomes in key measures during Phase 2a trials.
Safety and Efficacy: The clinical data indicates a favorable safety profile and a wide therapeutic window for ORX750, with plans to initiate a registrational program in Q1 2026.
Advancements in Other Candidates: ORX142 has demonstrated a differentiated profile in Phase 1 studies, leading to plans for patient studies starting in Q1 2026, while ORX489 is progressing through IND enabling studies.
Leadership in Neuroscience: Centessa aims to establish a strong position in the emerging class of orexin agonists, building a long-term growth platform in neuroscience with multiple candidates in development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.580
Low
27.00
Averages
38.75
High
62.00
Current: 27.580
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
- Acquisition Scale: Eli Lilly announced it will acquire Centessa Pharmaceuticals, a company focused on sleep-wake disorder drugs, for up to $7.8 billion, which is expected to significantly enhance Lilly's market position in sleep medicine.
- Clear Strategic Intent: Through this acquisition, Lilly aims to expand its product portfolio, particularly in the treatment of sleep disorders, to meet the growing market demand and drive future revenue growth.
- Positive Market Reaction: The market reacted positively to the acquisition news, with analysts generally believing that this move will enhance Lilly's innovation capabilities and competitive edge, especially in the rapidly evolving biopharmaceutical industry.
- Financial Impact Assessment: Although the acquisition amounts to $7.8 billion, Lilly anticipates achieving a return on investment in the coming years by integrating Centessa's R&D pipeline and market resources, thereby strengthening its overall financial health.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
LLP Investigates Centessa's Transaction with Lilly for Fiduciary Breaches
- Transaction Details: In the deal between Centessa and Lilly, shareholders will receive $38 per share in cash plus contingent value rights worth up to $9, indicating a high return potential in the merger but raising concerns about board conduct.
- Regulatory Investigation: LLP is investigating whether Centessa's board has breached fiduciary duties to all shareholders, particularly regarding restrictions on competing transactions and potential penalties, which could impact corporate governance.
- Contingent Value Rights: The transaction includes contingent value rights with milestone payments of $2, $5, and $2 upon FDA approvals, reflecting Centessa's potential gains in drug development but adding complexity to the deal.
- Insider Benefits: Centessa insiders will receive substantial benefits under change of control arrangements, raising concerns about whether they prioritize personal interests over those of all shareholders, potentially affecting investor confidence.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages shareholders of Apellis and Centessa Pharmaceuticals plc (NASDAQ:CNTA) to understand their legal rights, as the latter's deal involves $38.00 per share in cash plus a contingent value right worth up to $9.00, aiming to ensure fair treatment for shareholders.
- Asset Sale Impact: Allbirds, Inc. (NASDAQ:BIRD) sold its intellectual property and other assets for $39 million, and Halper Sadeh LLC may seek increased compensation and additional disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors in the past, highlighting its influence in protecting investor rights.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
- Acquisition Scale: Eli Lilly announced it will acquire Centessa Pharmaceuticals, a company focused on sleep-wake disorder drugs, for up to $7.8 billion, which is expected to significantly enhance Lilly's market position in sleep medicine.
- Clear Strategic Intent: Through this acquisition, Lilly aims to expand its product portfolio, particularly in the treatment of sleep disorders, to meet the growing market demand and drive future revenue growth.
- Positive Market Reaction: The market reacted positively to the acquisition news, with analysts generally believing that this move will enhance Lilly's innovation capabilities and competitive edge, especially in the rapidly evolving biopharmaceutical industry.
- Financial Impact Assessment: Although the acquisition amounts to $7.8 billion, Lilly anticipates achieving a return on investment in the coming years by integrating Centessa's R&D pipeline and market resources, thereby strengthening its overall financial health.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
LLP Investigates Centessa's Transaction with Lilly for Fiduciary Breaches
- Transaction Details: In the deal between Centessa and Lilly, shareholders will receive $38 per share in cash plus contingent value rights worth up to $9, indicating a high return potential in the merger but raising concerns about board conduct.
- Regulatory Investigation: LLP is investigating whether Centessa's board has breached fiduciary duties to all shareholders, particularly regarding restrictions on competing transactions and potential penalties, which could impact corporate governance.
- Contingent Value Rights: The transaction includes contingent value rights with milestone payments of $2, $5, and $2 upon FDA approvals, reflecting Centessa's potential gains in drug development but adding complexity to the deal.
- Insider Benefits: Centessa insiders will receive substantial benefits under change of control arrangements, raising concerns about whether they prioritize personal interests over those of all shareholders, potentially affecting investor confidence.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages shareholders of Apellis and Centessa Pharmaceuticals plc (NASDAQ:CNTA) to understand their legal rights, as the latter's deal involves $38.00 per share in cash plus a contingent value right worth up to $9.00, aiming to ensure fair treatment for shareholders.
- Asset Sale Impact: Allbirds, Inc. (NASDAQ:BIRD) sold its intellectual property and other assets for $39 million, and Halper Sadeh LLC may seek increased compensation and additional disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors in the past, highlighting its influence in protecting investor rights.
See More
